 |
|
Breast Cancer Trial Results
1. New Targeted Fluorescent-Imaging Compound Allows Researchers to Detect Viable Cancer Cells in Mice 3
(Posted: 12/08/2008) - Researchers have developed a new type of imaging compound that allows them to visualize viable breast cancer cells that have spread to the lungs in mice. The compound binds to a protein called HER2, which is found on the surface of some breast cancer cells, and it glows, or fluoresces, only when taken inside living cells. This method of targeting and activation allowed researchers to detect specific types of live cancer cells in a mouse model of breast cancer.
2. Shorter Course of Radiation Might Be Just as Effective with Early Breast Cancer 4
(Posted: 05/23/2000, Updated: 10/14/2008) - For some women with early breast cancer, a shorter, more intense course of radiation therapy after surgery may be just as effective as the standard longer course, according to updated results presented at the 2008 annual meeting of the American Society for Therapeutic Radiation and Oncology.
3. Denosumab May Help Prevent Bone Loss Related to Use of Aromatase Inhibitors 5
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
4. Osteoporosis Drug Raloxifene Does Not Protect Against Coronary Heart Disease, But Reduces Breast Cancer Risk 6
(Posted: 08/28/2006, Updated: 07/17/2008) - The drug raloxifene (Evista®) did not prevent heart problems in postmenopausal women with, or at high risk for, coronary heart disease, according to the July 13, 2006, issue of the New England Journal of Medicine.
5. Zoledronic Acid Improves Early Breast Cancer Treatment 7
(Posted: 06/19/2008, Reviewed: 09/16/2008) - The addition of zoledronic acid (Zometa) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
1 2 8 3 9 4 10 Next > 8
|
Table of Links
| 1 | http://www.cancer.gov/cancertopics/types/breast |
| 2 | http://www.cancer.gov/clinicaltrials/search |
| 3 | http://www.cancer.gov/newscenter/pressreleases/HER2imagingKobayashi |
| 4 | http://www.cancer.gov/clinicaltrials/results/shorter-course0802 |
| 5 | http://www.cancer.gov/clinicaltrials/results/denosumab0908 |
| 6 | http://www.cancer.gov/clinicaltrials/results/raloxifene0806 |
| 7 | http://www.cancer.gov/clinicaltrials/results/zoledronic-acid0608 |
| 8 | http://www.cancer.gov/clinicaltrials/results/breast?keyword=any+breast&page=2 |
| 9 | http://www.cancer.gov/clinicaltrials/results/breast?keyword=any+breast&page=3 |
| 10 | http://www.cancer.gov/clinicaltrials/results/breast?keyword=any+breast&page=4 |
|
|
